Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943537 · ClinicalTrials.gov registry record · Phase 2
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
A Phase 2 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT03943537 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 87 participants.
The verdict
NCT03943537, a Phase 2 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.
Interventions
- DRUG Intranasal Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2024-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943537
The ClinicalTrials.gov registry entry for NCT03943537 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal Insulin is the first listed.
NCT03943537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03943537 about?
NCT03943537 is a clinical study titled "Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders". This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.
What is the current status of trial NCT03943537?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2019-10-01. Estimated completion is 2024-02-23.
What interventions are being tested in trial NCT03943537?
The interventions under investigation include: Intranasal Insulin (DRUG).
Who is sponsoring clinical trial NCT03943537?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.